nach oben

Wiener klinische Wochenschrift

Erschienen in:

28.04.2020 | original article

Plasma lipids in patients with inflammatory bowel disease

Observations on the associations between lipid indices and coronary flow reserve

verfasst von: Şeref Kul, MD, Zuhal Çalışkan, MD, Tolga Sinan Güvenç, MD, Rengin Çetin Güvenç, MD, Mustafa Çalışkan, MD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 11-12/2020

Einloggen, um Zugang zu erhalten

Summary

Background and aims

Patients with inflammatory bowel disease (IBD) are at increased risk for coronary artery disease (CAD), even after adjusting for traditional risk factors for atherosclerosis. While inflammation is widely regarded as the pathophysiologic link between IBD and CAD, the exact mechanisms are largely unknown. This study was conducted to investigate the association of lipid parameters and indices with coronary flow reserve and markers of inflammation in IBD patients.

Methods

A total of 73 patients with IBD and 26 healthy controls were enrolled. Patients in the IBD arm were either in remission or had mild disease activity. Lipid parameters, C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were analyzed using standard laboratory techniques. Coronary flow reserve (CFR) was measured using two-dimensional echocardiography.

Results

Both CRP and ESR were higher and CFR was significantly lower in IBD patients, but there were no differences in terms of lipid parameters or indices; however, patients with IBD and a CFR <2.0 had significantly higher triglyceride (TG) level (155.0 (80.0) mg/dl vs. 108.0 (68.0) mg/dl, p < 0.001) and there was a strong trend towards lower high-density lipoprotein (HDL) cholesterol (40.0 (8.5) mg/dl vs. 45.0 (10.0) mg/dl, p = 0.05) level in the latter group when compared to patients with a CFR ≥2.0. The atherogenic index of plasma (AIP), measured as log(TG/HDL-C) had the best predictive value for CFR in IBD group and was an independent predictor of CFR after multivariate adjustment for confounders (unstandardized coefficient: −0.75, 95% CI: (−1.13)–(−0.37)), β = −0.41, p = <0.001).

Conclusion

The atherogenic index of plasma is a marker for reduced CFR in IBD patients and could be useful to screen those at risk for early atherogenesis and CAD.

Vorheriger Artikel Evaluation of the Manchester triage system for patients with acute coronary syndrome

Nächster Artikel Detection of atrial shunt lesions with a single echocardiographic parameter

Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol. 2008;6:41–5.PubMed

Ha C, Magowan S, Accortt NA, Chen J, Stone CD. Risk of arterial thrombotic events in inflammatory bowel disease. Am J Gastroenterol. 2009;104:1445–51.PubMed

Yarur AJ, Deshpande AR, Pechman DM, Tamariz L, Abreu MT, Sussman DA. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol. 2011;106:741–7.PubMed

Rungoe C, Basit S, Ranthe MF, Wohlfahrt J, Langholz E, Jess T. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut. 2013;62:689–94.PubMed

Singh S, Singh H, Loftus EV Jr, Pardi DS. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12:382–93.PubMed

Zanoli L, Inserra G, Castellino P. Increased cardiovascular risk in subjects with a low prevalence of classic cardiovascular risk factors: the inflammatory bowel disease paradox. Trends Cardiovasc Med. 2015;25(8):705–6. https://doi.org/10.1016/j.tcm.2015.04.001.CrossRefPubMed

Prasad M, Hermann J, Gabriel SE, Weyand CM, Mulvagh S, Mankad R, et al. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol. 2014;12(3):168–76.PubMedPubMedCentral

Rungoe C, Nyboe Andersen N, Jess T. Inflammatory bowel disease and risk of coronary heart disease. Trends Cardiovasc Med. 2015;25(8):699–704. https://doi.org/10.1016/j.tcm.2015.03.010.CrossRefPubMed

Sappati Biyyani RS, Putka BS, Mullen KD. Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease. J Clin Lipidol. 2010;4:478–82.PubMed

10.

Romanato G, Scarpa M, Angriman I, et al. Plasma lipids and inflammation in active inflammatory bowel diseases. Aliment Pharmacol Ther. 2009;29:298–307.PubMed

11.

Ripolles Piquer B, Nazih H, Bourreille A, et al. Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. Metabolism. 2006;55:980–8.PubMed

12.

Koutroubakis IE, Malliaraki N, Vardas E, et al. Increased levels of lipoprotein (a) in Crohn’s disease: a relation to thrombosis? Eur J Gastroenterol Hepatol. 2001;13:1415–9.PubMed

13.

Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA. 2007;298(7):776.PubMed

14.

Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993–2000.

15.

Onat A, Can G, Kaya H, et al. Atherogenic index of plasma (log10 triglyceride/high-density lipoprotein cholesterol) predicts high blood pressure, diabetes, and vascular events. J Clin Lipidol. 2010;4:89–98.PubMed

16.

Edwards MK, Blaha MJ, Loprinzi PD. Atherogenic index of plasma and triglyceride/high-density lipoprotein cholesterol ratio predict mortality risk better than individual cholesterol risk factors, among an older adult population. Mayo Clin Proc. 2017;92(4):680–1. https://doi.org/10.1016/j.mayocp.2016.12.018.CrossRefPubMed

17.

Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem. 2001;34(7):583–8.PubMed

18.

Quispe R, Manalac RJ, Faridi KF, et al. Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: the Very Large Database of Lipids‑4 (VLDL-4) study. Atherosclerosis. 2015;242(1):243–50.PubMed

19.

Arcaro G, Zenere BM, Travia D, Zenti MG, Covi G, Lechi A, et al. Non-invasive detection of early endothelial dysfunction in hypercholesterolaemic subjects. Atherosclerosis. 1995;114:247–54.PubMed

20.

Dayanikli F, Grambow D, Muzik O, Mosca L, Rubenfire M, Schwaiger M. Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. Circulation. 1994;90:808–17.PubMed

21.

Clarkson P, Celermajer DS, Powe AJ, Donald AE, Henry RM, Deanfield JE. Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation. 1997;96:3378–83.PubMed

22.

Bernstein CN, Eliakim A, Fedail S, Fried M, Gearry R, Goh KL, et al. World Gastroenterology Organisation global guidelines inflammatory bowel disease: update August 2015. J Clin Gastroenterol. 2016;50(10):803–18.PubMed

23.

Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70:439–44.PubMed

24.

Turner D, Seow CH, Greenberg GR, Griffiths AM, Silverberg MS, Steinhart AH. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7(10):1081–8.PubMed

25.

Castelli WP, Abbott RD, McNamara PM. Summary estimates of cholesterol used to predict coronary heart disease. Circulation. 1983;67(4):730–4.PubMed

26.

Nunes SO, Piccoli de Melo LG, Pizzo de Castro MR, Barbosa DS, Vargas HO, Berk M, et al. Atherogenic index of plasma and atherogenic coefficient are increased in major depression and bipolar disorder, especially when comorbid with tobacco use disorder. J Affect Disord. 2015;172:55–62. https://doi.org/10.1016/j.jad.2014.09.038.CrossRefPubMed

27.

Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity. 2013;38:1092–104.PubMedPubMedCentral

28.

Theocharidou E, Gossios TD, Giouleme O, Athyros VG, Karagiannis A. Carotid intima-media thickness in patients with inflammatory bowel disease: a systematic review. Angiology. 2014;65:284–93.PubMed

29.

Zanoli L, Cannavo M, Rastelli S, Di PL, Monte I, Di GM, et al. Arterial stiffness is increased in patients with inflammatory bowel disease. J Hypertens. 2012;30:1775–81.PubMed

30.

Caliskan Z, Gokturk HS, Caliskan M, Gullu H, Ciftci O, Ozgur GT, et al. Impaired coronary microvascular and left ventricular diastolic function in patients with inflammatory bowel disease. Microvasc Res. 2015;97:25–30. https://doi.org/10.1016/j.mvr.2014.08.003.CrossRefPubMed

31.

Caliskan Z, Keles N, Gokturk HS, Ozdil K, Aksu F, Ozturk O, et al. Is activation in inflammatory bowel diseases associated with further impairment of coronary microcirculation? Int J Cardiol. 2016;223:176–81. https://doi.org/10.1016/j.ijcard.2016.08.141.CrossRefPubMed

32.

Sellke FW, Armstrong ML, Harrison DG. Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates. Circulation. 1990;81:1586.PubMed

33.

Laaksonen R, Janatuinen T, Vesalainen R, Lehtimäki T, Elovaara I, Jaakkola O, et al. High oxidized LDL and elevated plasma homocysteine contribute to the early reduction of myocardial flow reserve in healthy adults. Eur J Clin Invest. 2002;32(11):795–802.PubMed

34.

Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 1995;91(9):2488.PubMed

35.

Nissen SE. The Jupiter trial: key findings, controversies, and implications. Curr Cardiol Rep. 2009;11(2):81–2.PubMed

36.

Guthrie RM. Use of rosuvastatin in preventing vascular events in patients with elevated C‑reactive protein. Commentary. Postgrad Med. 2010;122(2):169–71. https://doi.org/10.3810/pgm.2010.03.2136.CrossRefPubMed

37.

Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990;82(2):495–506.PubMed

38.

Fujimoto K, Hozumi T, Watanabe H, Shimada K, Takeuchi M, Sakanoue Y, et al. Effect of fluvastatin therapy on coronary flow reserve in patients with hypercholesterolemia. Am J Cardiol. 2004;93(11):1419–21, A10.PubMed

39.

Yokoyama I, Ohtake T, Momomura S, Nishikawa J, Sasaki Y, Omata M. Reduced coronary flow reserve in hypercholesterolemic patients without overt coronary stenosis. Circulation. 1996;94:3232–8.PubMed

40.

Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem. 1992;38(9):1632.PubMed

41.

Talmud PJ, Edwards KL, Turner CM, Newman B, Palmen JM, Humphries SE, et al. Linkage of the cholesteryl ester transfer protein (CETP) gene to LDL particle size: use of a novel tetranucleotide repeat within the CETP promoter. Circulation. 2000;101(21):2461.PubMed

42.

Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996;276(11):875.PubMed

43.

Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, Wilson PW, et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation. 2006;113(1):20.PubMed

44.

Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med. 1993;94(4):350.PubMed

45.

Rosenson RS, Davidson MH, Hirsh BJ, Kathiresan S, Gaudet D. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014;64(23):2525–40.PubMed

46.

Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115(4):450.PubMed

47.

Ballantyne CM, Grundy SM, Oberman A, Kreisberg RA, Havel RJ, Frost PH, et al. Hyperlipidemia: diagnostic and therapeutic perspectives. J Clin Endocrinol Metab. 2000;85(6):2089.PubMed

48.

Lundman P, Eriksson M, Schenck-Gustafsson K, Karpe F, Tornvall P. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. Circulation. 1997;96(10):3266–8.PubMed

49.

Hozumi T, Eisenberg M, Sugioka K, Kokkirala AR, Watanabe H, Teragaki M, et al. Change in coronary flow reserve on transthoracic Doppler echocardiography after a single high-fat meal in young healthy men. Ann Intern Med. 2002;136(7):523–8.PubMed

50.

Maddox TM, Stanislawski MA, Grunwald GK, Bradley SM, Ho PM, Tsai TT, et al. Nonobstructive coronary artery disease and risk of myocardial infarction. JAMA. 2014;312(17):1754–63.PubMedPubMedCentral

51.

Chow BJ, Small G, Yam Y, Chen L, Achenbach S, Al-Mallah M, et al. Incremental prognostic value of cardiac computed tomography in coronary artery disease using CONFIRM: COroNary computed tomography angiography evaluation for clinical outcomes: an InteRnational Multicenter registry. Circ Cardiovasc Imaging. 2011;4(5):463–72.PubMed

52.

Rigo F, Cortigiani L, Pasanisi E, Richieri M, Cutaia V, Celestre M, et al. The additional prognostic value of coronary flow reserve on left anterior descending artery in patients with negative stress echo by wall motion criteria: a transthoracic vasodilator stress echocardiography study. Am Heart J. 2006;151:124–30.PubMed

53.

Sicari R, Rigo F, Cortigiani L, Gherardi S, Galderisi M, Picano E. Additive prognostic value of coronary flow reserve in patients with chest pain syndrome and normal or near-normal coronary arteries. Am J Cardiol. 2009;103(5):626–31. https://doi.org/10.1016/j.amjcard.2008.10.033.CrossRefPubMed

Titel: Plasma lipids in patients with inflammatory bowel disease
Observations on the associations between lipid indices and coronary flow reserve
verfasst von: Şeref Kul, MD
Zuhal Çalışkan, MD
Tolga Sinan Güvenç, MD
Rengin Çetin Güvenç, MD
Mustafa Çalışkan, MD
Publikationsdatum: 28.04.2020
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 11-12/2020
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-020-01649-2

Springer Medizin Österreich

Summary

Background and aims

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11-12/2020

DFP: Kardiogener Schock

Heart failure disease management programs in Austria 2019

Veranstaltungstipps

Clinical-Pathological Conference Series from the Medical University of Graz

Frailty as a predictor of all-cause mortality and readmission in older patients with acute coronary syndrome

Evaluation of the Manchester triage system for patients with acute coronary syndrome